Market Cap : 2.83 B | Enterprise Value : 2.79 B | PE Ratio : At Loss | PB Ratio : |
---|
NAS:PTCT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:PTCT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
PTC Therapeutics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2022 was $-1.78. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2022 was $-7.38.
PTC Therapeutics's EPS (Diluted) for the three months ended in Mar. 2022 was $-1.78. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2022 was $-7.38.
PTC Therapeutics's EPS without NRI for the three months ended in Mar. 2022 was $-1.78. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2022 was -7.38.
During the past 3 years, the average EPS without NRI Growth Rate was -39.30% per year. During the past 5 years, the average EPS without NRI Growth Rate was -21.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 11 years, PTC Therapeutics's highest 3-Year average EPS without NRI Growth Rate was 18.40% per year. The lowest was -48.70% per year. And the median was 3.10% per year.
The historical data trend for PTC Therapeutics's EPS (Basic) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
PTC Therapeutics's Basic EPS for the fiscal year that ended in Dec. 2021 is calculated as
Basic EPS (A: Dec. 2021 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-523.901 | - | 0) | / | 70.466 | |
= | -7.43 |
PTC Therapeutics's Basic EPS for the quarter that ended in Mar. 2022 is calculated as
Basic EPS (Q: Mar. 2022 ) | = | (Net Income | - | Preferred Dividends) | / | Shares Outstanding (Basic Average) |
= | (-126.726 | - | 0) | / | 71.215 | |
= | -1.78 |
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-7.38
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Thank you for viewing the detailed overview of PTC Therapeutics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.
Southwell David P | director | C/O INOTEK PHARMACEUTICALS CORPORATION 91 HARTWELL AVENUE LEXINGTON MA 02421 |
Jacobson Allan Steven | director | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Peltz Stuart Walter | director, officer: Chief Executive Officer | PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Utter Christine Marie | officer: SVP, Finance & CAO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Boulding Mark Elliott | officer: Exec. VP and CLO | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Hill Emily Luisa | officer: Chief Financial Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Svoronos Dawn | director | C/O MEDIVATION, INC. 525 MARKET ST., 36TH FLOOR SAN FRANCISCO CA 94105 |
Pauwels Eric | officer: Chief Business Officer | 550 HILLS DRIVE BEDMINSTER NJ 07921 |
Klein Matthew B. | officer: Chief Development Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Schmertzler Michael | director | 1300 VALLEY ROAD NEW CANAAN CT 06840 |
Souza Marcio | officer: Chief Operating Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Almstead Neil Gregory | officer: Chief Technical Ops Officer | C/O PTC THERAPEUTICS, INC. 100 CORPORATE COURT SOUTH PLAINFIELD NJ 07080 |
Reeve Emma | director | C/O PAREXEL INTERNATIONAL CORPORATION 195 WEST STREET WALTHAM MA 02451 |
Steele Glenn Jr Md Phd | director | 250 TECHNOLOGY PARK LAKE MARY FL 32746-6232 |
Zeldis Jerome B | director | 8767 E. VIA DE VENTURA, SUITE 190 SCOTTSDALE AZ 85258 |
From GuruFocus
Other Sources
By Zacks 2022-04-04
By Zacks 2021-05-27
By Zacks 2021-02-25
By Zacks 2022-02-15
By Zacks 2022-02-18
By Seekingalpha 2022-01-12
By Zacks 2021-05-04
By Seekingalpha 2020-10-30
By Zacks 2021-10-21
By Zacks 2020-08-18
By Zacks 2021-04-30
By Seekingalpha 2021-01-23